Kala Pharmactcls Rg

Kala Bio, a clinical‑stage biopharma, leverages nanotechnology to develop therapies for rare eye diseases. Its Phase 2b candidates KPI‑012 (corneal defect) and KPI‑014 (inherited retinal disorders) underscore strong market potential in ophthalmology.

Headquarters: United States (USA)

Website: Visit Site 🔗
Type: Corporation

Company Profile

Sector: Professional Services
Industry: Nanotechnology Research

Employees: 38
HQ: Arlington

Unlock the full potential.

Get access to Relative P/E Ratio Valuation Histogram.

Upgrade

Traded Instruments

+ Add Instrument 1

Symbol	Name	Type	Exchange	Currency	ISIN	Status	Actions
KALA	Kala Pharmactcls Rg Cap: 0.0B	EQUITY	NMS	USD	US4831191030	Active	📈